You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Measuring Infant Pain Objectively using Sensor Fusion and Machine Learning Algorithms
SBC: AUTONOMOUS HEALTHCARE INC Topic: R41Newborns are routinely and frequently exposed to pain during Neonatal ICUNICUcarePain assessments in neonates are difficultlabor intensivesubjective and unreliableoften resulting in excessive or inadequate analgesiaOur overall objective is to measure infant pain objectivelyreliablyand in real timeWe will extract pain related information from multiple non invasive sensorsdevelop a sensor fusion fra ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Medical Device to Assess the Viability of Tissue Prior to Skin Grafting
SBC: Spectral Md, Inc. Topic: DHP17A006The primary objective of this Phase II proposal is to construct and validate the portable SpectralMD DeepView imaging technology designed previously in Phase I. This device allows surgeons to quickly and objectively assess tissue viability in burn surgery prior to skin grafting. DeepView uses machine learning and multispectral imaging to generate quantitative prognostic images with easily interpre ...
STTR Phase II 2018 Department of DefenseDefense Health Agency -
Medical Electro-Textile Sensor Simulation
SBC: LR TECHNOLOGIES, Inc. Topic: DHP17A001In this topic, we plan to design a vital EMF sensor to work under any conditions. The sensor will be integrated with smart clothing and using e-textile materials.
STTR Phase II 2018 Department of DefenseDefense Health Agency -
Mitochondrial Dysfunction in HAART: Point of Care Tests
SBC: MITOSCIENCES, INC Topic: NIGMSDESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Mobile App Targeting Meth Use, HIV Sex Risks and ART Adherence for Gay/Bisexual Men
SBC: COG ANALYTICS, LLC Topic: NIDADESCRIPTION (provided by applicant): Methamphetamine use among gay and bisexually identified men (GBM) and other men who have sex with men (MSM) is strongly associated with HIV infection due to the concomitant high-risk sexual behaviors that often occur while using the drug. As a result, HIV prevalence is significantly higher among MSM that report frequent use of methamphetamine and highest among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Multipurpose reversible terminators
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: NHGRIDESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
MyFAP: A Multimedia Intervention for Adolescents and Young Adults with FAP
SBC: Radiant Creative Group, LLC Topic: NCIDESCRIPTION (provided by applicant): In this Phase II STTR application, we will build upon work conducted in our successful Phase I project which established the technical merit, acceptability and feasibility of developing a Web-based intervention, MyFAP.org, for adolescents and young adults (AYAs) with familial adenomatous polyposis (FAP). The main research goal of Phase II is to evaluate the eff ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy
SBC: HNB Therapeutics LLC Topic: NIASummary Glucocorticoid induced osteoporosis is the most common cause of secondary osteoporosisand the primary cause before ageIt affects overof the general populationwhereinare womenIn postmenopausal women and men agedand overtreatment would be recommended in at least half based on theAmerican College of Rheumatology guidelinesAdult stem cells are a promising class of regenerative cellssome lineag ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Neuroprotective therapy of stroke with HUCNC and simvastatin
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health